Overview
Addressing the Barriers to Medical Treatment for Alcohol Use Disorder (AUD)
Case Challenges to Improve AUD
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Alcohol use disorder (AUD) has a significant burden on patients and their loved ones. AUD is treatable with medication and psychosocial counseling; however, patients with AUD are undertreated particularly in the primary care setting. This case challenge activity will replicate real-world practice and provide evidence-based treatment recommendations for AUD, including pharmacotherapy, along with supporting expert commentary. Cases include diagnosing a patient resistant to accepting an AUD diagnosis in addition to managing a patient with complex comorbidities. Gain confidence in identifying and managing patients with AUD and motivate your patients to follow through with seeking, recommending, and adhering to treatment.
This activity is intended for primary care and emergency medicine clinicians who see patients with or at risk of AUD.
AUD is a highly prevalent condition that has significant burden on patients, their families and loved ones, and society, yet is frequently underrecognized and undertreated. There are significant gaps in screening and diagnosis of AUD, but the largest gap remains in treatment of AUD, with only less 10% of patients receiving medication. Both in primary care and specialist settings, clinicians indicate lack of knowledge and skepticism on the efficacy of AUD medications highlighting a need for education in this area. In line with several studies, addiction specialists also believe that education of primacy care providers on existing medications is the most important next step to increase prescribing of AUD medications, amplifying the need for such education to improve AUD care and patient outcomes.
Upon completion of this activity, learners will be able to:
• Introduce routine screening strategies in clinical practice to enhance identification of patients with AUD
• Adopt processes for brief intervention with referral to treatment
• Apply treatment guidelines and clinical trial evidence in treatment selection for patients with AUD
• Introduce routine screening strategies in clinical practice to enhance identification of patients with AUD
• Adopt processes for brief intervention with referral to treatment
• Apply treatment guidelines and clinical trial evidence in treatment selection for patients with AUD
Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Alkermes.
 | Jon Grant, MD, JD, MPH (Chair) Professor, Department of Psychiatry & Behavioral Neuroscience University of Chicago Pritzker School of Medicine Chicago, IL |
 | Joji Suzuki, MD (Faculty) Director, Division of Addiction Psychiatry Program Director, BWH Addiction Medicine Fellowship Program Assistant Professor, Harvard Medical School Boston, MA |
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
All of the relevant financial relationships listed for these individuals have been mitigated.
The following financial relationships have been provided:
Jon Grant, MD, (Chair)
Research Grant: Biohaven and Janssen Pharmaceuticals
Joji Suzuki, MD, (Faculty)
Research Support: Indivior
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Off-label topiramate and gabapentin for alcohol-use disorder.
ACHL and the University of Chicago Pritzker School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier mforcier@achlcme.org
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
